Plain-English translation of NCT07548996 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether dimethyl fumarate can help slow down or stop the loss of -producing cells in adults with type 1 diabetes. Right now, type 1 diabetes occurs when the immune system mistakenly attacks the cells in the pancreas that make . The study wants to see if this medication, given alongside regular therapy, can help preserve the pancreas's remaining ability to produce .
Type 1 diabetes happens when the body's immune system destroys -producing cells, and currently there is no way to stop this damage or restore lost cell function. This trial exists to test whether this medication might be able to slow that process down and help people keep some of their own production, which could improve their overall health and make managing diabetes easier.
You likely qualify if…
You likely don't qualify if…
If you are selected, you will be assigned to one of two groups: one group will take the new medication twice daily in addition to their regular therapy, while the other group will continue with therapy alone. Either way, you will visit the clinic multiple times over 24 weeks of active treatment, followed by 52 weeks of follow-up visits where the doctors will test your blood sugar control, measure your remaining production, and monitor for any side effects. The entire study lasts about one year from start to finish.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China